LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2019-65-3-386-392

Published 01.03.2019

Konstantin Laktionov⁺⁻
Yelena Reutova⁺⁻
Natalya Kormosh⁺⁻
Valeriy Breder⁺⁻
A. Gorokhov⁺⁻

Konstantin Laktionov

N.N. Blokhin National Medical Research Centre of oncology» of the Health Ministry of Russia

Yelena Reutova

N.N. Blokhin National Medical Research Centre of oncology» of the Health Ministry of Russia

Natalya Kormosh

N.N. Blokhin National Medical Research Centre of oncology» of the Health Ministry of Russia

Valeriy Breder

N.N. Blokhin National Medical Research Centre of oncology» of the Health Ministry of Russia

A. Gorokhov

Pirogov Russian National Research Medical University

##article.numberofdownloads## 303

##article.numberofviews## 370

PDF (Русский)

Keywords

ALK НМРЛ
LORLATINIB
ALK NSCLC

How to Cite

Laktionov, K., Reutova, Y., Kormosh, N., Breder, V., & Gorokhov, A. (2019). LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT. Voprosy Onkologii, 65(3), 386–392. https://doi.org/10.37469/0507-3758-2019-65-3-386-392

Abstract

Background: Lorlatinib is the third generation inhibitor of ALK and ROS1 tyrosine kinase has shown activity in patients with crisotinib-refractory ALK-positive NSCLC most of whom had CNS metastases. We report results of the overall and intracranial antitumor activity of patients with crisotinib-refratory ALK-positive NSCLC. Methods: Patients with ALK and ROS1-positive NSCLC who had progressed after crisotinib and at least one regimen of chemotherapy with or without CNS metastases with ECOG PS was 0-2 and adequate organ functions were given lorlatinib 100 mg orally once daily continuously. Primary endpoint -overall and intracranial objective response, secondary endpoint - safety of lorlatinib. Results: Since January 2017 to July 2018 39 patients were enrolled: ALK+- 36, ROS1+ - 3 pts. Median age 49 years. 27 pts had brain metastases. Objective response was achieved in 22 pts (56, 4%) - 3 complete (7,7%) and 19 partial (48,7%) responses. 16 pts (41%) had stabilization as the best response, 1 ALK+ pt progressed...

https://doi.org/10.37469/0507-3758-2019-65-3-386-392

##article.numberofdownloads## 303

##article.numberofviews## 370

PDF (Русский)

References

Soda M., Choi YL., Enomoto M. Takada S. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer // Nature. - 2007. - Vol. 448(7153). - P. 561-566. - DOI: 10.1038/nature05945

Sahu A., Prabhash K., Noronha V. et al. Crizotinib: A comprehensive review // South Asian J. Cancer. - 2013. -Vol. 2(2). - P. 91-97. - DOI: 10.4103/2278-330X.110506

Costa D.B., Shaw A.T., Ou S.H. et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases // J. Clin. Oncol. - 2015. - Vol. 33(17). - P 1881-1888. - DOI: 10.1200/JCO.2014.59.0539

Лактионов К.К., Реутова Е.В., Саранцева К.А. ALK-позитивный немелкоклеточный рак легкого и методы его лечения: обзор литературы // Фарматека. - 2015. - № 18 (311). - C.76-79.

Лактионов К.К., Реутова Е.В., Ардзинба М.С., Мещерякова Н.А. Таргетная терапия немелкоклеточного рака легкого при реарранжировке ROS1 // Научно-практический журнал для врачей «Медицинский совет». - 2017. - № 6. - С. 51-55.

Gadgeel S.M., Gandhi L., Riely G.J. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study // Lancet Oncol. - 2014. - Vol. 15(10). - P. 1119-1128. - DOI: 10.1016/S1470-2045(14)70362-6

Shaw A.T., Engelman J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer // N. Engl. J. Med. - 2014. - Vol. 370. - P. 2537-2539.

Gainor J.F., Tan D.S., De Pas T. et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib // Clin. Cancer Res. - 2015. - Vol. 21. - P. 2745-2752. - DOI: 10.1158/1078-0432.CCR-14-3009

Duruisseaux M., Besse B., Cadranel J. et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study // Oncotarget. - 2017. - Vol. 8(13). - P. 21903-21917. - DOI: 10.18632/oncotarget.1

Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future // J. Clin. Oncol. - 2013. - Vol. 31(8). - P1105-1111. - doi: 10.1200Д1Ш.2012.44.5353.

Sharma G.G. Mota I., Mologni L. et al. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes // Cancers (Basel). - 2018. - Vol. 10(3). - P E62. - DOI: 10.3390/cancers10030062

Solomon B.J., Besse B., Bauer T.M. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study // Lancet Oncol. - 2018. - Vol. 19(12). - P. 1654-1667. - DOI: 10.1016/S1470-2045

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Tatyana Borisova, Arif Allakhverdiev, Yuriy Gerasimov, Nadezhda Meshcheryakova, Mikhail Dolgushin, Valeriy Breder, Konstantin Laktionov, Sevil Alieva, Stanislav Ivanov, Sergey Tkachev, Aleksey Nazarenko, S. Loraeva, STEREOTACTIC HYPO-FRACTIONAL RADIOTHERAPY OF PATIENTS WITH LUNG CANCER I-IIA CLINICAL STAGE: THE ROLE OF SUVMAX ASSESSMENT IN 18F-FDG PET/CT FOR MONITORING TREATMENT OUTCOMES , Voprosy onkologii : Vol. 63 No. 4 (2017)
Tatyana Borisova, M. Ardzinba, A. Fedorova, Valeriya Glebovskaya, Oksana Trofimova, Dimitr Marinov, Yelena Reutova, Stanislav Ivanov, Sevil Alieva, Nadezhda Meshcheryakova, Valeriy Breder, Konstantin Laktionov, Sergey Tkachev, Aleksey Nazarenko, N. Marinichenko, HIGH-TECH RADIATION THERAPY WITH LOCAL DOSE ESCALATION IN CHEMO-RADIATION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. PREDICTORS OF EFFECTIVENESS , Voprosy onkologii : Vol. 64 No. 6 (2018)
Konstantin Laktionov, Alla Arzumanyan, Larisa Bolotina, Valeriy Breder, Natalya Buevich, A. Danilova, Anna Zinkovskaya, Anna Kornietskaya, M. Kramchaninov, Ye. Kushniruk, Dilorom Latipova, Fedor Moiseenko, Tatyana Nikitina, Mariya Okruzhnova, Sergey Orlov, Rashida Orlova, N. Porfireva, Svetlana Protsenko, Kseniya Sarantseva, Daniil Stroyakovskiy, Yelena Filippova, Tatyana Ionova, EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY , Voprosy onkologii : Vol. 65 No. 1 (2019)
Konstantin Laktionov, Andrey Zaretskiy, Denis Yudin, Dmitriy Shagin, Valeriy Breder, REBIOPSY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AS THE BASIS OF INDIVIDUALIZED TREATMENT , Voprosy onkologii : Vol. 63 No. 3 (2017)
Denis Fedyaev, V. Ignateva, Yelena Derkach, Sergey Zyryanov, Konstantin Laktionov, Tatyana Semiglazova, COMPARATIVE PHARMACOECONOMIC EVALUATION OF THE USE OF AFATINIB AND GEFITINIB IN THERAPY FOR LUNG CANCER , Voprosy onkologii : Vol. 63 No. 1 (2017)
Konstantin Laktionov, Denis Yudin, Yuliya Maevskaya, Lyubov` Vladimirova , Dimitr Marinov, Merab Ardzinba, Amir Abdullaev, Irina Popova, Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation. , Voprosy onkologii : Vol. 67 No. 2 (2021)
Tatyana Borisova, S. Tkachev, S. Ivanov, S. Alieva, O. Trofimova, V. Glebovskaya, Valeriy Breder, K. Laktionov, Dimitr Marinov, A. Abdullaev, RADIATION THERAPY IN MULTIMODAL TREATMENT OF PATIENTS WITH PLEURAL MESOTHELIOMA. LITERATURE REVIEW AND ANALYSIS OF OWN OBSERVATIONS , Voprosy onkologii : Vol. 66 No. 5 (2020)
Valeriy Breder, Boris Dolgushin, Anatoliy Kukushkin, Igor Trofimov, Vladislav Kosyrev, Lyudmila Kostyakova, Eduard Virshke, Konstantin Laktionov, Irina Dzhanyan, M. Pitkevich, TRANSARTERIAL CHEMOEMBOLIZATION(TACE) EFFICACY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA(HCC): CAN SIGNIFICANT PROGNOSTIC FACTORS BE REVEALED? , Voprosy onkologii : Vol. 64 No. 6 (2018)
M. Natrusova, Valeriy Breder, Irina Dzhanyan, Oleg Olisov, Murad Novruzbekov, Yekaterina Moroz, P. Murashova, M. Pitkevich, Konstantin Laktionov, BRAIN METASTASES AFTER LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: THE CHOICE OF THERAPY , Voprosy onkologii : Vol. 65 No. 6 (2019)
Konstantin Laktionov, A. Kazakov, Kseniya Sarantseva, Yelena Reutova, A. Arzumanyan, N. Moskalyuk, THE ROLE OF LIQUID BIOPSY IN THE CHOICE OF TACTICS FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER , Voprosy onkologii : Vol. 66 No. 5 (2020)

1 2 > >>